Skip to main content
OpenTrials
Completed

NCT Number: NCT05303168

Prevalence and Impact of COVID-19 on Maternal and Infant Health in African Populations

There is growing evidence that COVID-19 threatens maternal and perinatal health. Pregnant women are at higher risk of severe complications (severe pneumonia, hospitalizations, intensive care unit admission, invasive mechanical ventilation, extracorporeal membrane oxygenation) and death compared to age-matched non-pregnant women. On the other hand, the number of confirmed COVID-19 cases reported in sub-Saharan Africa (SSA) continues to increase, where the highest maternal mortality rates in the world are registered. The World Health Organization (WHO) estimates that this region alone accounted for roughly two-thirds (196 000) of all maternal deaths in 2017, which among other reasons is explained by the inequalities in access to quality antenatal care (ANC) services and the low numbers of skilled health workers in the region. The spread of SARS-CoV-2 in SSA is threatening the already fragile health services, affecting mainly the most vulnerable populations such as pregnant women.

This project aims to describe the burden and effects of SARS-CoV-2 infection during pregnancy in women living in malaria endemic areas and high prevalence of HIV infection. Pregnant women attending ANC clinics in selected sites from Libreville and Lambaréné (Gabon) and Manhiça (Mozambique) will be enrolled in a cohort study to determine the frequency of SARS-CoV-2 infection and COVID-19 during pregnancy and its effects on maternal and neonatal health. Participants will be tested for SARS-CoV-2 infection whenever reporting respiratory symptoms suggestive of COVID-19 during routine ANC follow-up and six weeks after the end of pregnancy. The presence of antibodies (IgG/IgM) against SARS CoV-2 in blood samples will be determined. The clinical presentation of COVID-19 in pregnancy will be also characterised, and the incidence of infection during pregnancy and the risk factors of maternal and neonatal morbidity and mortality associated with SARS-CoV-2 infection and the frequency of mother- to- child transmission of SARS-CoV-2 will be assessed.

The findings of this project will contribute to the understanding of the impact of SARS-CoV-2 and COVID-19 among pregnant women living in SSA countries where malaria and HIV infections are highly prevalent.

Completed

Looking for future studies?

Notify Me

Key information

Sex eligibility

Female

Study type

Observational

Primary location

Centre de Recherches Médicales de Lambaréné (CERMEL), Lambaréné, Gabon

Loading trial locations.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Permanent resident in the study area
  • Agreement to deliver in the study site's maternity(ies) wards

Exclusion criteria

  • Planning to move out the study area in the following 7 months from enrolment

Treatment and study plan

Primary outcomes

  1. Prevalence of antibodies (Ig G and/or Ig M positive) against SARS-CoV-2 among pregnant women at delivery

    Time frame: 7 months

Secondary outcomes

  1. Incidence of SARS-CoV-2 infection during pregnancy

    Time frame: 7 months

  2. Maternal and neonatal morbidity due to SARS-CoV-2 infection during pregnancy

    Time frame: 7 months

  3. Maternal and neonatal mortality due to SARS-CoV-2 infection during pregnancy

    Time frame: 7 months

  4. Prevalence of pregnancy and perinatal adverse outcomes

    Time frame: 7 months

  5. Rate of vertical transmission of SARS-CoV-2 from infected mothers to their offspring, during the prenatal and perinatal period

    Time frame: 7 months

  6. CD4 cell counts

    Time frame: 7 months

  7. HIV viral load

    Time frame: 7 months

  8. Frequency of malaria parasitaemia at delivery (from maternal sample collected at delivery)

    Time frame: 7 months

Sponsors and collaborators

Lead sponsor

Barcelona Institute for Global Health

Other

Collaborators

  • Bernhard Nocht Institute for Tropical Medicine
  • Centre de Recherche Médicale de Lambaréné
  • Centro de Investigação em Saúde de Manhiça
  • Universität Tübingen

Registry information

Official study title

Prevalence and Impact of SARS-CoV-2 Infection on Maternal and Infant Health in African Populations (MA-CoV)

Acronym: MA-CoV

Important dates

Study start
2021
Primary completion
2023
Study completion
2024
First posted
Mar 31, 2022
Registry last updated
Sep 20, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.